Asthma Inflammation Extends Into Even the Smallest Airways1
- The small (<2 mm)3 airways are a primary site of asthma inflammation1,2
- Most inhaled corticosteroids (ICSs) aren’t formulated to get there
- As a result, small-airway inflammation is typically uncontrolled1
For Your Asthma Patient, Uncontrolled Small-Airway Inflammation Could Mean:
- Persistent symptoms1
- Increased asthma exacerbations1
- Small-airway anatomic changes, which can potentially lead to irreversible lung damage1
QVAR®: The Solution for Small-Airway Inflammation
QVAR Is a Small-Particle, Extra-Fine Aerosol Solution4
- The small particle size of QVAR (MMAD of 1.1 µm) penetrates more effectively into the small
airways than large-particle suspension formulations5
- QVAR delivers a greater mass of small particles to the peripheral lung6
- QVAR achieves high lung deposition of up to 58%*
- - Compared with 12 to 13% for fluticasone CFC1,5,7
- - Minimizes deposition in the mouth and throat5
- - Distributes evenly throughout the entire airway5
QVAR’s Deposition Is Consistent Even When Inhaler Technique Is Poor7
QVAR’s Anti-inflammatory Treatment Reaches the Entire Airway5
References:
- Martin RJ. Therapeutic significance of distal airway inflammation in asthma. J Allergy Clin Immunol. 2002;109(2):S447-S460.
- Yanai M, Sekizawa K, Ohrui T, et al. Site of airway obstruction in pulmonary disease: direct measurement of intrabronchial pressure. J Appl Physiol. 1992;72:1016-1023.
- Thongngarm T, Silkoff PE, Kossack WS, Nelson HS. Hydrofluoroalkane-134A beclomethasone or chlorofluorocarbon fluticasone: effect on small airways in poorly controlled asthma. J Asthma. 2005;42:257-263.
- Zeidler M, Corren J. Hydrofluoroalkane formulations of inhaled corticosteroids for the treatment of asthma. Treat Respir Med. 2004;3(1):35-44.
- Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone*: a cross-over study in healthy volunteers. Chest. 2002;122:510-516.
- Winkler J, Hochhaus G, Derendorf H. How the lung handles drugs: pharmacokinetics and pharmacodynamics of inhaled corticosteroids. Proc Am Thor Soc. 2004;1:356-363.
- Leach C. Effect of formulation parameters on hydrofluoroalkane-beclomethasone dipropionate drug deposition in humans. J Allergy Clin Immunol. 1999;104:S250–S252.
- Data on File. Teva Specialty Pharmaceuticals LLC.
- Cripps A, Riebe M, Schulze M, et al. Pharmaceutical transition to non-CFC pressurized metered dose inhalers. Respir Med. 2000;94:S3-S9.
- Newman S, Salmon A, Nave R, et al. High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir Med. 2006;100:375-384.
101181